Navigation Links
Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
Date:6/9/2008

SUNNYVALE, Calif., June 9 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a preclinical study evaluating PCI-32765, an orally available, selective inhibitor of Bruton's tyrosine kinase, or Btk, in collagen induced arthritis, an established animal model for rheumatoid arthritis (RA). The data were presented during the Federation of Clinical Immunology Societies (FOCIS) meeting being held this week in Boston, MA.

Researchers examined the impact of treatment with PCI-32765 on mouse models of rheumatoid arthritis at disease onset, and with established active disease. Treatment prevented further joint swelling when animals were dosed at early stages of disease. In animals with advanced disease, treatment with PCI-32765 reduced inflammation and induced regression of disease with approximately 50% reduction in histopathologic score after only five days of dosing. Treatment with PCI-32765 was found to inhibit mast cell function and to prevent allergic reaction, with passive cutaneous analphylaxis inhibited by more than 95%. In other studies, human B-cell activation was shown to be selectively inhibited by drug treatment in vitro. PCI-32765 also inhibited the proliferation of, and induced apoptosis in, multiple B-cell lymphoma cell lines in vitro, suggesting that Btk inhibition could be a novel drug target in lymphoma.

"This study suggests that treatment with PCI-32765 causes a potent combined blockade of both B-cell and mast cell activation," said Joseph J. Buggy, Ph.D., vice president of research for Pharmacyclics. "This dual blockade may account for the preclinical efficacy seen in established arthritis models and holds promise for potential use in humans with advanced RA and other immune
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
2. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
3. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
4. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
5. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
6. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
9. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
10. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
11. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Lazarus Effect, a medical device company focused ... facilitate removal of blood clots, announced today that ... issued a new patent (U.S. Patent Number 8,795,305) ... TM and ReCover TM devices. ... stent-retriever (stentriever) with an integrated, novel, cover-based protection ...
(Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
(Date:7/24/2014)... -- In any given hospital in the country at any ... one hospital-acquired infection, according to the Centers of Disease ... prove fatal. And as increased surveillance has shown that ... per year, infection control efforts have drifted to the ... stronger emphasis is being placed upon innovative and comprehensive ...
Breaking Medicine Technology:Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 2Employees, Equipment and the Environment: Top Infection Prevention Focuses in Hospitals 3
...  Medtronic, Inc, one of the world,s largest medical device ... U.S. Department of Justice (DOJ), the Office of the ... Services, and four relators in a qui tam suit ... in the U.S., including pacemakers and implantable cardioverter defibrillators ...
... A three-drug combination treatment for the blood cancer multiple myeloma ... patients, according to a multi-center study led by Andrzej ... the multiple myeloma program at the University of Chicago Medical ... of the phase I-II study on Dec. 12, 2011, ...
Cached Medicine Technology:Settlement Announced in Medtronic Qui Tam Case 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 2Drug Combination Highly Effective for Newly Diagnosed Myeloma Patients, Study Finds 3
(Date:7/24/2014)... Mellon University, working with high-throughput data generated by ... have devised a computational method to determine how ... turn malignant and as they respond to potential ... genes interact with each other in laboratory-grown cells ... the online journal PLOS Computational Biology . ...
(Date:7/24/2014)... Denver, CO (PRWEB) July 24, 2014 In ... the United States has officially put an end to criminal ... legislation marks a new era for marijuana reform in Washington ... in America. The new law replaces criminal penalties for possession ... fine. Growing, selling and the possession of more than an ...
(Date:7/24/2014)... from Penn Medicine shows that incisionless transcatheter aortic ... stay by 30 percent and has no impact ... conventional transfemoral TAVR, which requires an incision in ... the current issue of Circulation: Cardiovascular Interventions ... aortic valve without a traditional open-heart surgical approach. ...
(Date:7/24/2014)... Lynn E. Taylor, M.D., director of The ... the July, 2014 Rhode Island Medical Journal ... eliminating hepatitis c virus infection (hep c or ... capacity to address other health challenges, and improve ... the United States, Taylor says, include lack of ...
(Date:7/24/2014)... 2014 On October 24-25th, 2014, hundreds of ... the Embassy Suites LAX North for DiabetesSisters’ power-packed weekend conference. ... the first time it has convened Los Angeles, CA area. ... to open the entire event to both women with diabetes ... its kind worldwide for women with diabetes, the event offers ...
Breaking Medicine News(10 mins):Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3Health News:Washington D.C. Decriminalizes Marijuana 2Health News:Penn study: Incisionless transcatheter aortic valve replacement surgery cuts hospital length of stay 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 2Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 3Health News:Miriam Hospital physician advocates awareness, collaboration to combat peaking hep C virus 4Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 2Health News:DiabetesSisters Brings Conference for Women with Diabetes Los Angeles for the First Time 3
... If you want to lose the kilos you,ve put on over ... to appetite play an important role in your likelihood of regaining ... highest levels of leptin and lowest levels of ghrelin are more ... Doctors often have to deal with patients who, after sticking to ...
... that a bacterium inside the worm acts as a ,disguise, ... it in an ineffective way. The bacteria protect the ... are removed with antibiotics, the immune system responds appropriately, releasing ... Antibiotics are successful against the parasite, but the long treatment ...
... HealthDay Reporter , TUESDAY, Jan. 11 (HealthDay News) -- ... and Advil, can raise the risk of heart ... suggests. Swiss researchers analyzed the results of 31 ... medications are called, and concluded that cardiovascular risk needs ...
... HealthDay Reporter , TUESDAY, Jan. 11 (HealthDay ... cancer surgery experience urinary incontinence afterward, but new research ... problems for a significant number of them. After ... pelvic exercises and bladder control techniques -- the researchers ...
... , TUESDAY, Jan. 11 (HealthDay News) -- The steady, ... and there has been an alarming increase in the number ... The abortion rate in 2008 was 19.6 per 1,000 women ... peak of 29.3 per 1,000 women, according to the nonprofit ...
... Launched on December 2, 2010, Healthy People 2020 ... health of all Americans. A key component, Education for ... People 2020 goals. Formulated by the Healthy People Curriculum ... objectives provides a vehicle for promoting the discussion and ...
Cached Medicine News:Health News:'Yo-yo' effect of slimming diets explained 2Health News:Study sheds new light on river blindness parasite 2Health News:Certain Painkillers Appear to Boost Odds for Heart Attack 2Health News:Certain Painkillers Appear to Boost Odds for Heart Attack 3Health News:Therapy May Help Cut Incontinence After Prostate Surgery 2Health News:Therapy May Help Cut Incontinence After Prostate Surgery 3Health News:Decline in U.S. Abortion Rate Stalls, Report Finds 2Health News:10-year roadmap for reaching public health education goals 2Health News:10-year roadmap for reaching public health education goals 3Health News:10-year roadmap for reaching public health education goals 4
Reliable and Affordable. The Schuco 3000 Nebulizer by Allied has been designed to offer a compact style that provides worry-free affordable nebulizer therapy....
... CNBT technology, which relieves the practitioner of the ... HOPE allows you the ability to mix medications ... be easier, with a length of oxygen tubing ... the HOPE nebulizer into an inexpensive alternative to ...
... utilizing Vibrating Mesh Technology to efficiently ... from Asthma, COPD or other respiratory ... size and handy carrying case that ... them. Powerful delivery comparable to table-top ...
... dilution nebulizer allows the clinician to deliver up ... into the side port for precise high flow ... for normal flow patients, delivers 8-12 lpm in ... side port. For your high flow needs, DHD ...
Medicine Products: